Welcome to our dedicated page for NuCana plc news (Ticker: $NCNA), a resource for investors and traders seeking the latest updates and insights on NuCana plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NuCana plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NuCana plc's position in the market.
NuCana (NASDAQ: NCNA) has released its financial results for Q1 2024, ending March 31, 2024. The company reported a net loss of £6.8 million, an improvement from £7.9 million in Q1 2023. Cash and cash equivalents stood at £12.9 million, down from £17.2 million at the end of 2023. Loss per share was £0.13, reduced from £0.15 in the comparable period.
Key developments include the full enrollment of a Phase 2 study involving 182 colorectal cancer patients and encouraging results from NUC-7738 combined with pembrolizumab in patients resistant to PD-1 inhibitors. NuCana's clinical programs, including NUC-3373 and NUC-7738, are on track for significant data readouts in 2024. The company expects its cash runway to extend into Q1 2025.
NuCana aims to announce multiple clinical data points in 2024, focusing on metastatic colorectal cancer and melanoma treatments.
NuCana plc (NASDAQ: NCNA) has announced that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Stock Market. The company had previously been notified of non-compliance due to its closing bid price falling below $1.00 for 30 consecutive business days. However, after maintaining a minimum closing bid price of $1.00 or more for 10 consecutive business days, NuCana has now met the requirement, as confirmed by a Notification Letter from Nasdaq.